Can You Legally Buy BPC-157 and Other Peptides? What the FDA Is Actually Considering

MEDISEARCHER NEWS
United States · Medication Regulation · 9 October 2026

In brief: The Trump administration is reportedly considering an interim policy that could expand access to BPC-157, TB-500 and several other peptides through compounding pharmacies. The FDA has not approved these peptides, and as of 9 October 2026 MediSearcher has not identified a new FDA rule or guidance putting the reported policy into effect.

Last updated: 9 October 2026

What happened this week?

On October 7, The Washington Post reported that the Trump administration is considering temporarily allowing access to certain unapproved peptides through compounding pharmacies while the longer regulatory process continues.

According to the report, discussions have included the possibility of using interim enforcement discretion, potentially alongside safeguards such as patient disclosures and adverse-event reporting.

MediSearcher checked the FDA’s current Human Drug Compounding Policies and Rules and its current information on bulk drug substances under Section 503A. As of October 9, we have not identified a newly published FDA policy implementing the reported proposal.

Which peptides are involved?

The current debate follows a two-day meeting of the FDA’s Pharmacy Compounding Advisory Committee (PCAC) on July 23 and 24, 2026.

The FDA’s official meeting record shows that seven peptide-related substances were considered for possible inclusion on the 503A Bulks List.

Important: the conditions in this table are the uses the FDA evaluated during the compounding review. They should not be read as FDA-approved indications or as evidence that the peptides have been proven safe and effective for those uses.

Did the FDA approve BPC-157 and the other peptides?

No.

This is the most important distinction in the story.

The July meeting concerned whether particular bulk drug substances should be eligible for use in certain compounded drugs under Section 503A. It was not an FDA drug-approval process.

The advisory committee ultimately recommended six of the seven peptide-related substances. Reuters reported after the meeting that the recommendations were non-binding and that the FDA would make the final regulatory decision.

The FDA’s own briefing material also shows an important detail that can be lost in simplified accounts of the vote: FDA staff had proposed that the peptide substances under review not be included on the 503A Bulks List. The advisory committee subsequently voted to recommend six of them despite those concerns.

That disagreement helps explain why the regulatory position remains more complicated than headlines suggesting that the “FDA approved peptides.”

What is the 503A Bulks List?

Section 503A of the Federal Food, Drug, and Cosmetic Act provides a framework under which qualifying state-licensed pharmacies, federal facilities and licensed physicians can compound drugs for individual patients.

According to the FDA’s Section 503A guidance, compounders generally may use a bulk drug substance if it:

• complies with an applicable United States Pharmacopeia or National Formulary monograph, if one exists;
• is a component of an FDA-approved drug product where an applicable monograph does not exist; or
• appears on the FDA’s 503A Bulks List when the other conditions do not apply.

The FDA also requires bulk substances used under the provision to meet additional conditions, including requirements concerning certificates of analysis and manufacturing establishments.

Being placed on the 503A Bulks List therefore matters because it can create a route for a substance to be used in qualifying prescription compounding.

But inclusion on that list still does not mean the resulting compounded product is an FDA-approved drug.

What is “enforcement discretion”?

This is another distinction that matters in understanding the October reports.

The FDA already uses interim enforcement policies while it evaluates some substances nominated for the 503A Bulks List. Under certain conditions, the agency may state that it does not intend to take enforcement action against qualifying compounders while a substance remains under evaluation.

The FDA describes this approach in its January 2025 interim policy on Section 503A bulk substances.

Enforcement discretion is not FDA approval. It is a regulatory enforcement policy describing circumstances in which the agency does not intend to take action while the formal regulatory process continues.

The October proposal reported by The Washington Post appears to involve a possible interim approach for the peptides considered by the advisory committee. The final details, substances covered and conditions imposed could still change.

Can you get BPC-157 from a compounding pharmacy now?

The newly reported proposal does not, by itself, create a new federal right to obtain BPC-157 or the other peptides.

The July advisory committee vote was a recommendation rather than final FDA action, and MediSearcher has not identified an FDA announcement implementing the newly reported October policy as of October 9.

Patients should therefore be cautious about websites or social-media posts claiming that BPC-157 or the other peptides are now “FDA approved,” “FDA legalized” or newly authorized for unrestricted sale because of the July vote.

A compounded drug is also fundamentally different from an FDA-approved drug. FDA-approved products go through the agency’s approval process for safety, effectiveness and manufacturing quality. Compounded drugs are not FDA-approved in that way.

Why is the FDA concerned about compounded peptides?

The debate is not simply about whether patients should have access.

The FDA’s July meeting materials contain extensive reviews of the individual substances and the evidence available for their proposed uses.

Peptide manufacturing can also present particular quality challenges. FDA materials discuss issues such as peptide-related impurities, incomplete or truncated peptide sequences, aggregation and characterization of the active ingredient.

These concerns matter because products bought through gray-market websites may be marketed as peptides for human use without having gone through the approval and manufacturing controls required for FDA-approved medicines.

The FDA maintains a separate list of bulk drug substances that may present significant safety risks in compounding. It includes several other substances popular in the peptide and performance/wellness market, including GHRP-6, ibutamoren and ipamorelin.

Does this mean the FDA is opening the door to all peptides?

No.

The July committee considered seven specifically nominated peptide-related substances. Six received positive recommendations and one — emideltide, also known as DSIP — did not.

Other peptides and peptide-like substances have separate regulatory histories and cannot be assumed to have the same status.

For example, the FDA’s safety-risk material identifies potential concerns with some other substances used in compounding. For ipamorelin acetate, FDA cites concerns including potential immunogenicity associated with aggregation or peptide-related impurities. For ibutamoren mesylate, the agency identifies a potential congestive-heart-failure safety signal.

Those examples illustrate why a policy involving BPC-157, KPV, TB-500, MOTS-c, Semax or Epitalon would not amount to a general legalization or approval of “peptides.”

Why consider broader access if the evidence is limited?

This is the central tension behind the policy debate.

Demand for peptides already exists, and many products are available through online sellers operating outside conventional prescription-pharmacy channels. Supporters of broader compounding access argue that bringing some of that demand into licensed pharmacies could provide more oversight than an uncontrolled gray market.

Critics argue that greater availability could expose more patients to substances for which evidence on safety and effectiveness remains limited.

The July advisory committee votes themselves show that this was not a straightforward scientific consensus. The committee recommended the six peptides despite FDA staff recommending against their inclusion.

The question now facing regulators is therefore not simply whether peptide use exists. It is whether a regulated compounding pathway can address existing demand without implying a level of safety or effectiveness that has not been established through the FDA drug-approval process.

What happens next?

There are now two regulatory developments to watch.

1. The formal 503A process. The FDA must decide what to do with the advisory committee’s recommendations and proceed through the appropriate regulatory process before the substances are formally added to the 503A Bulks List.
2. The reported interim policy. The administration may announce an enforcement-discretion approach allowing some peptide compounding before that longer process is complete.

MediSearcher will update this article if the FDA or Department of Health and Human Services formally announces an interim peptide policy or the regulatory status of these substances changes.

What patients should know

The immediate takeaway is simpler than the regulatory process behind it:

• The FDA has not approved BPC-157, KPV, TB-500, MOTS-c, Semax or Epitalon through this process.
• An FDA advisory committee recommended the six substances for the 503A compounding list.
• The committee’s recommendations are not themselves final FDA action.
• A new interim access policy is reportedly under consideration, but MediSearcher has not identified an implementing FDA announcement as of October 9.
• Compounded drugs should not be confused with FDA-approved drugs.
• A policy covering these six substances would not mean that all peptides have been approved or cleared for compounding.

Patients considering any compounded medication should discuss the potential benefits, risks and regulatory status with an appropriately licensed healthcare professional and verify that any pharmacy involved is properly licensed.

Frequently asked questions

Is BPC-157 FDA approved?

No. BPC-157 has not become an FDA-approved drug as a result of the July 2026 advisory committee vote. The committee recommended BPC-157-related bulk substances for possible inclusion on the 503A Bulks List used in pharmacy compounding. That is a different regulatory process from FDA drug approval.

Did the FDA legalize BPC-157 in 2026?

No final FDA action identified by MediSearcher as of October 9 supports describing BPC-157 as newly “legalized” or FDA approved. The advisory committee recommended its inclusion on the 503A Bulks List, and an interim enforcement policy is reportedly being considered.

Which peptides did the FDA advisory committee recommend?

The committee recommended BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. It did not recommend emideltide, also known as DSIP.

Does a 503A recommendation mean a peptide is safe and effective?

No. A recommendation concerning eligibility for pharmacy compounding is not an FDA determination that a substance is safe and effective for a particular medical indication.

Will patients need a prescription?

Section 503A generally concerns patient-specific pharmacy compounding associated with prescriptions, but the exact conditions of any newly announced interim peptide policy will matter. Patients should not assume that reports of a possible policy change authorize unrestricted over-the-counter peptide sales.

---

Sources and verification

MediSearcher reviewed the following primary regulatory material and reporting when preparing this article:

• US Food and Drug Administration: July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting and supporting materials
• US Food and Drug Administration: Bulk Drug Substances Used in Compounding Under Section 503A
• US Food and Drug Administration: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A
• US Food and Drug Administration: Human Drug Compounding Policies and Rules
• US Food and Drug Administration: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
• The Washington Post: Trump administration paving way for temporary sale of some unapproved peptides, October 7, 2026
• Reuters: FDA advisers recommend relaxing US rules on compounding peptides, July 24, 2026

This article is for informational purposes only and does not provide medical advice. Regulatory policies and the status of compounded drugs can change. Check current FDA information and consult an appropriately licensed healthcare professional before making treatment decisions.